Press coverage about SciClone Pharmaceuticals (NASDAQ:SCLN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.647912614508 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
SciClone Pharmaceuticals (SCLN) remained flat at $$11.15 on Friday. SciClone Pharmaceuticals has a 1 year low of $8.55 and a 1 year high of $11.43.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact SciClone Pharmaceuticals (SCLN) Stock Price” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-sciclone-pharmaceuticals-scln-stock-price.html.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.